Durvalumab & NSCLC | Cancer Projections in 2040 | New Dosing for CetuximabApril 14, 2021 | Oncology Cardiology Durvalumab Reduces Mortality Risk vs Chemo in NSCLC With PD-L1 Expression Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells. Read full article Hematology Estimated Projection of US Cancer Incidence and Death to 2040 In this Original Investigation from JAMA, the authors attempt to discover how the landscape of cancer incidences and deaths will change in the next two decades. The findings suggest marked changes in the landscape of cancer incidence and deaths by 2040, emphasizing the importance of cancer screening, early detection, and prevention to guide research, health care, and health policy efforts. Read full article Internal Medicine FDA Approves Novel Dosing Regimen for Cetuximab in CRC, Head and Neck Cancer The approval of the new cetuximab (Erbitux) dosage – 500 mg/m2 as a two-hour IV infusion every two weeks – was based on population pharmacokinetic (PK) modeling analyses and provides an alternative option to the previously approved weekly dose. Cetuximab can be dosed alone or in combination with chemotherapy. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS